Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Hydra Biosciences

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

FDA clears Jardiance combo for type 2 diabetes

Combination treatment Synjardy is fifth drug to come from Boehringer/Lilly diabetes alliance

Eli Lilly HQ

Lilly and Boehringer launch Lantus biosimilar in UK

Competition in the insulin drug market begins to heat up

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

- PMLiVE

Boehringer COPD drug ‘could give patients more independence’

New data shows Stiolto improves patients’ lives

Boehringer Ingelheim headquarters

Boehringer returns to growth in first half

German firm back on track after a tough sales period

Boehringer Ingelheim headquarters

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

Boehringer Ingelheim headquarters

Boehringer plans new filings for Giotrif in lung cancer

Firm to file drug for squamous cell carcinoma of the lung

- PMLiVE

Boehringer’s ASCO blog picks up digital excellence award

Work by Ogilvy HealthPRwins Prescription Products/Patient Health prize

- PMLiVE

Boehringer’s Spiriva combo approved in first EU markets

Combination therapy available countries including the UK, Ireland and Spain

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

Novel anticoagulant antidotes prove their worth

Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links